Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Somatostatins have been the most game-changing drug in the treatment landscape of gastroenteropancreatic neuroendocrine tumors, explained Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center.
Transcript
What role do somatostatin analogs play in the treatment of gastroenteropancreatic neuroendocrine tumors?
I’d say it’s probably the most central pharmaceutical in the treatment of these tumors. I think it’s probably been the most game-changing drug as far as the landscape’s concerned, over the last 20 years. They’re fairly low toxicity drugs. Their biggest toxicity is really that they’re costly and they’re monthly, so they require a little more effort out of the patients and that they’re going to have to continue to come in for monthly injections. But, they’re still going to be the most central pharmacologic agent and, often time, our best tool in the toolbelt, if you will.
Are there any patient characteristics or biomarkers that indicate response to treatment?
So, there’s a lot of things that are being looked at. Centrally, I think imaging is playing a bigger and bigger role, even in the community-based setting. So, things like DOTATATE PET/CT, 68Ga-DOTATATE PET/CT, has really changed the way that we look at it because you can get a much more comprehensive biomarker of the entire tumor by dong some nuclear imaging, and that gives you an idea of what receptors light up and what drugs you may be able to use and is an appropriate indicator of how well things like peptide receptor radionuclide therapy (PRRT) will work.
Whether it’s a really appropriate indicator of how well things like somatostatin analogs will work is still a little matter of debate. That evidence is not nearly as robust. But, that gives you a pretty good comprehensive picture of the tumor. There has been a lot of look at SSTR2A, which is a marker on the outside of the cells that they can stain for pathologically and how that’s being linked for responses to therapies is certainly being used as criteria for a couple of clinical trials at hand.
And then, the biggest indicators are classically what we’ve always used to just grade these things pathologically, which is what do they look like under a microscope, how aggressive do they look, what is the Ki-67, which continues to be an extremely useful prognostic tool. Those types of factors are still, I would say, the most central things that we use to try and make treatment decisions up front.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More